Eurofarma Ventures

Marco Billi, a member of the controlling Billi family, leads Eurofarma Ventures and drives investment decisions. The unit operates under the broader governance of Eurofarma Laboratórios S.A., where the Billi family holds majority control. This centralized decision-making reflects the family-office-like agility within a corporate structure.

Eurofarma Ventures invests across both biotech and health-tech services. Its mandate spans therapeutic biotech platforms, AI-driven diagnostics, digital health tools, and synthetic biology. The parent company's emphasis on oncology and specialty drugs has sharpened the focus on precision-medicine-related investments.

Deal flow comes through Eurofarma's business-development network, relationships with Brazilian and international health-tech accelerators, and direct outreach to innovation hubs in the United States and Israel. The parent company's market position as one of Brazil's largest pharmaceutical manufacturers gives the venture arm visibility into clinical and regulatory needs that independent GPs miss.

Eurofarma Ventures targets companies globally, with disclosed activity in Brazil, the United States, and Israel. Its Latin American manufacturing and distribution scale gives it a structural advantage when evaluating startups seeking commercial entry into Brazil's SUS-covered and private-pay markets.

The fund is a corporate venture capital unit of Eurofarma Laboratórios S.A., not a separate family-office structure. However, the Billi family's controlling ownership gives it a governance profile that resembles a family-backed vehicle more than a typical corporate VC answering to public shareholders.

Eurofarma Ventures makes direct equity investments in early-stage and growth-stage companies. There is no public disclosure of fund-of-fund commitments or GP stakes. Its corporate mandate centers on direct strategic deployment rather than passive allocations to external funds.

Eurofarma Ventures does not invest in sectors unrelated to its parent's pharmaceutical and health-care focus. Areas such as fintech, consumer apps, or heavy industry are outside its mandate. The fund also specifically avoids later-stage buyouts that would require operational control of mature companies.